MELD score [HR=1.12 (1.06–1.18); p<0.001] predicted mortality at day-90 (figure 1).

**Conclusions**
Terlipressin infusion is safe and effective in ACLF patients. Non-response to terlipressin is dependent on baseline sCr and ACLF grade. Terlipressin non-response and MELD scores predict mortality in ACLF patients with HRS-AKI.

**STUDY ON CORRELATION BETWEEN SERUM FERRITIN LEVELS AND LIVER STIFFNESS ASSESSED BY FIBROSCAN IN PATIENTS WITH CHRONIC HEPATITIS C**

Ha Phuong Linh*, 2Le Thi Thu Hien, 1Dinh Cong Dang, 1Hoang Van Tiep. 1Department of Internal Medicine, 103 Cam Khe Clinic, Vietnam; 2Department of Internal Medicine, Thai Nguyen University of Medicine and Pharmacy, Vietnam

**Background**
Chronic hepatitis C is a major infectious disease which mainly causes of morbidity worldwide in patients with liver disease and liver transplantation. Raised ferritin levels play an important role in intervening the process which is associated with hepatic injury. Screening with non-invasive strategies can detect the disease at the early stage, and intervention could be initiated.

**Aims**
To determine the correlation between serum ferritin levels and liver stiffness values in patients of chronic hepatitis C.

**Methods**
A cross-sectional study was conducted at 103 Cam Khe Clinic from May 2019 to April 2020. 93 patients with chronic hepatitis C fulfilling inclusion criteria were included in this study. Liver fibrosis stages were appreciated using transient hepatic elastography by Fibroscan, the activities of serum liver function biomarker enzymes and serum ferritin levels were determined by the automated analyser.

**Results**
The average age of patients was 48 years, with men accounted for 78% of the total. The mean serum ferritin value was 148.19 ng/ml, liver stiffness measurements range from 12.5 to 75.5 kPa, with a median value of 17.39 ± 15.98 kPa. Significantly elevated levels of serum ferritin (p < 0.001), were detected in patients with severe fibrosis compared to mild fibrosis. The concentration of serum ferritin was increased with the evolution of fibrosis in all stages from F0 to F4, and this increase was significant (p<0.01) in cirrhotic patients (F4). There was a positive correlation between serum level of ferritin and the progression of fibrosis (0.979391) (r = 0.976).

**Conclusions**
There is a significant correlation between serum ferritin and liver stiffness. Serum ferritin concentration may be used as liver fibrosis biomarkers.

**STUDY ON FIBROSIS CHANGE WITH TRANSIENT ELASTOGRAPHY IN CHRONIC HEPATITIS B VIRUS TREATMENT WITH TENOFOVIR**

Ha Phuong Linh*, 2Le Thi Thu Hien, 1Hoang Van Tiep, 2Dinh Cong Dang, 2Nguyen Khac Hung Manh. 1Department of Internal Medicine, 103 Cam Khe Clinic, Vietnam; 2Department of Internal Medicine, Thai Nguyen University of Medicine and Pharmacy, Vietnam

**Background**
Tenofovir disoproxil fumarate (TDF) is one of the first optimal choices to be used in the treatment of chronic hepatitis B. FibroScan is non-invasive methods to assess liver fibrosis.

**Aims**
To evaluate the therapeutic effect of TDF on fibrosis via FibroScan after treatment.

**Methods**
This study was conducted in 63 chronic hepatitis B patients who had the indication of antiviral therapy at 103 Cam Khe Clinic from March 2019 to March 2020. All patients with chronic hepatitis B treated with TDF for 6 months. Liver fibrosis stages were appreciated using transient hepatic elastography by Fibroscan before and after 6 months of treatment.
Results The average age of patients was 46 years, with men accounted for 69% of the total. After treatment, normalization of ALT 71.26%, the viral response of 90.23%, HBV DNA below the detection level was 66.3%. Liver fibrosis evaluated by FibroScan before and after 6 months treatment were 7.15 ± 1.56 kPa, and 3.58 ± 1.19 kPa evaluated by FibroScan.

Conclusions TDF was effective for patients after treatment on liver fibrosis assessed by FibroScan in chronic hepatitis B patients.